Topical and Light-based Treatments for Basal Cell Carcinoma

June K. Robinson*, Claudia Hernandez, E. Ratcliffe Anderson, Brian Nickoloff

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Nonsurgical methods of treatment providing cure rates approaching those provided by surgery offer a significant advantage to patients with basal cell carcinoma (BCC) in certain anatomic locations. While intralesional interferon has been used to treat BCC with some success, the deliver method requires multiple visits to the doctor's office, which makes compliance a challenge for the patient. Initial success with light-based therapy of BCC over a decade ago has not evolved to the point where it is an effective, widely available treatment. The new class of immune response modifiers, represented by topical imiquimod cream, shows promise for providing topical treatment of early BCC. It is hoped that further developments of the class of drugs will produce an agent with fewer side effects and improved efficacy for nodular BCC.

Original languageEnglish (US)
Pages (from-to)171-176
Number of pages6
JournalSeminars in Cutaneous Medicine and Surgery
Issue number3
StatePublished - Sep 1 2003

ASJC Scopus subject areas

  • Surgery
  • Dermatology


Dive into the research topics of 'Topical and Light-based Treatments for Basal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this